Fig. 4

Effects of IACS-10759 treatment on tumour growth and protein markers. a Tumour growth time-course under chronic IACS-10759 treatment. Calliper measurements taken at t = 0, 48, 120, and 168 h were converted to volumes (n = 4 mice per group). Six consecutive, once daily doses of IACS-10759, or vehicle were administered, starting at 24 h after the first calliper measurement. For presentation, individual data points were normalised to the mean of the respective treatment group at t = 0 h. b Summarised results of IHC staining against (from left to right): Ki67, cleaved caspase 3, phospho-AMPK (Thr172), phospho-PDHA1 (S293) and GLUT1 performed in the respective treatment groups: Vehiclex1, IACSx1, Vehiclex6, IACSx6 (single or six, once-daily doses of vehicle or IACS-10759, respectively), quantified using HALO image analysis platform. One-tailed Student’s t test, performed separately for each of the two vehicle—IACS treatment durations (single dose and 6, once-daily doses, respectively) was used to test statistical significance of the results. P value classifications are summarized as follows: *, P ∈ (0.01–0.05 〉; **, P ∈ (0.001–0.01〉. Only statistically significant (P < 0.05) results are indicated on the graph. Each data point represents an H-score obtained from an image of a single stained section (n = 4 each for both drug treatment durations and their respective vehicle control groups). Error bars represent one standard deviation. c Example IHC images showing staining summarised in b, with (from left to right): Ki67, cleaved caspase 3, phospho-AMPK (Thr172), phospho-PDHA1 (S293) and GLUT1 and (from top to bottom): Vehiclex1, IACSx1, Vehiclex6, IACSx6. Scale bar indicates 100 μm